Mucinase StcE
Based on 1 Customer Validation
Mucinase StcE is a zinc metalloproteinase belonging to the M66 family, which is secreted by enterohemorrhagic Escherichia coli via the type II general secretion pathway. Mucinase StcE specifically recognizes and cleaves the 'T*XT' motif in mucin-type glycoproteins with α-O-glycans (such as MUC2, Mucin 7, Glycoprotein 340, CD45, CD43, C1 Esterase Inhibitor (HY-P991629), etc.). By degrading the mucus layer to reduce its viscosity, inhibiting complement cascade activation, and localizing complement regulatory factors to the cell membrane, Mucinase StcE helps bacteria penetrate the mucosal barrier, adhere to host cells, and evade immune clearance. Mucinase StcE can serve as a mucin-specific proteolytic tool for research on mucinous carcinomas derived from the colon, esophagus, and salivary glands.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Mucinase StcE (0.5-1 mg/mL) exists as a monomer in solution and forms a 1:1 complex with its substrate C1 Esterase Inhibitor (HY-P991629)[1].
Mucinase StcE (overnight; 37 °C) enables tissue enzymatic digestion, and spatial visualization of different MUC2 glycoforms and tumor-specific O-glycopeptides in mucinous carcinoma tissues is achieved via MALDI-MSI[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mucinase StcE (0.1 μg/μL, 0.05 mg/mL; overnight (13-23 hour); 37°C) enables spatial localization and glycoproteomic identification of T-antigen-dominant versican glycoforms in human salivary gland mucoepidermoid carcinoma specimens[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:archival formalin-fixed, paraffin-embedded tissue specimens (mucinous carcinoma patients)[2]
-
Dosage:0.1 µg/µL (sprayer-applied); 0.05 mg/mL (pipette-applied to tumor regions)
-
Administration:on-slide; overnight (13-23 hour) incubation at 37°C (for 0.05 mg/mL dose); one set of 15 passes (for 0.1 µg/µL dose)
-
Result:Enabled spatial mapping of MUC2 O-glycopeptides via MALDI-MSI, revealing distinct distribution patterns: Tn-only MUC2 glycopeptides clustered in specific tumor regions adjacent to fibrotic or non-mucinous malignant tissue, while glycoforms with both T and Tn antigens were diffusely distributed across the mucinous tumor, and T-only glycoforms localized near the tumor edge adjacent to adipose tissue.
Yielded 91.2% sequence coverage over the two PTS domains of MUC2 via LC-MS, with most localized O-glycans being Tn or T antigens; low-abundance core 2 structures, mono- and di-O-acetylated sialic acid-containing glycans, and a putative O-acetylated GalNAc modification were also identified.
Restricted StcE-derived O-glycopeptides exclusively within tumor boundaries.\nRevealed via MALDI-MSI that Tn-only MUC2 glycopeptides concentrated at a single tumor site bordering non-mucinous adenocarcinoma tissue, while T antigen-containing glycoforms spread over a larger portion of the tumor region.
Confirmed 91.2% sequence coverage over MUC2's two PTS domains via LC-MS, with dominant Tn and T antigen modifications, plus low-abundance modified glycans including di-O-acetylated sialic acid and putative O-acetylated GalNAc.
Restricted StcE-derived O-glycopeptides to tumor boundaries.
-
Animal Model:archival formalin-fixed, paraffin-embedded tissue specimens (mucinous carcinoma patients)[2]
-
Dosage:0.1 µg/µL (sprayer-applied); 0.05 mg/mL (pipette-applied to tumor regions)
-
Administration:on-slide; overnight (13-23 hour) incubation at 37°C (for 0.05 mg/mL dose); one set of 15 passes (for 0.1 µg/µL dose)
-
Result:Detected StcE-generated glycopeptides diffusely distributed across the tumor, with some spillover into adjacent parotid tissue via MALDI-MSI.
Revealed via LC-MS that glycopeptide results were dominated by versican, with core 1 and core 2 structures (with and without sialylation) localized on versican glycopeptides; most were decorated exclusively with T antigens, with very few Tn antigen-modified species.
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Mucinase StcE]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Mucinase StcE Related Classifications
HY-E70562 Related Classifications
Powered by Bioz